Cancer Pharmacogenomics and Targeted Therapies
Conference - Cambridge, United Kingdom
The development of new cancer therapies is increasingly guided by our understanding of the molecular basis of cancer. As worldwide efforts are beginning to provide a comprehensive description of the genomic, transcriptomic and epigenomic changes that occur in cancer, the field of cancer pharmacogenomics will be at the forefront of a new generation of rationally designed cancer therapies incorporating molecular biomarkers. These hold the promise of improved clinical responses by enabling the stratification of patients most likely to benefit from a specific treatment
This conference is aimed at scientists and clinician-scientists in academia or industry and will seek to address many of the key challenges in the design, development and clinical implementation of targeted cancer therapies
Scientific topics will include:
• Cancer Genomics
• Drugging the Cancer Genome
• Experimental and pre-clinical therapeutic models
• Combating drug resistance
• Molecular biomarkers in the clinic
(Courtesy of Discovering and validating molecular biomarkers, via olink.com)
Cancer Pharmacogenomics and Targeted Therapies
September 15, 2013 — September 17, 2013
Wellcome Trust Conference Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
